ESR1 and breast cancer: Therapeutic drugs for breast cancer have begun to diversify, and no new drugs targeting ER (two SERDs bazedoxifene and ospemifene, are not indicated for breast cancer, Additional file 1: Table S1, page 26) or aromatase have been approved since the approval of fulvestrant in 2002.